Skip to content

The Impact of Digital Health Management Interventions on the Prognosis of Heart Failure Patients: A Randomized Controlled Clinical Trial

The Impact of Digital Health Management Interventions on the Prognosis of Heart Failure Patients: A Randomized Controlled Clinical Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500111246
Enrollment
Unknown
Registered
2025-10-28
Start date
2025-12-01
Completion date
Unknown
Last updated
2025-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure

Interventions

Intervention Group:Receive personalized prognosis reports and individualized lifestyle guidance through the upgraded website (systematic push once a month with intelligent feedback), while the system
Control Group:Receive routine heart failure health education (distribution of standardized manuals, quarterly telephone follow-ups)

Sponsors

The First Affiliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. A clear diagnosis of heart failure (meeting the relevant criteria of the "Chinese Guidelines for the Diagnosis and Treatment of Heart Failure"), NYHA functional class II-III; 2. Age >= 18 years, with basic literacy and reading ability; 3. The patient owns a smartphone or the household has a stable internet connection and can perform basic online operations (or can be assisted by family members); 4. Informed consent, voluntarily participating in this study and signing the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Severe comorbidities with a life expectancy of less than 1 year (e.g., terminal malignancy, severe liver or kidney failure, etc.); 2. Acute coronary syndrome, stroke, major cardiac surgery, or interventional treatment within the past 3 months; 3. Presence of other serious heart diseases (e.g., severe valvular heart disease requiring surgery, acute myocarditis, cardiac tamponade, uncontrolled complex arrhythmias, etc.); 4. Cognitive impairment, mental illness, or any other condition that prevents completion of study follow-up and interventions; 5. Pregnant or breastfeeding women; 6. Individuals currently participating in other interventional clinical studies.

Design outcomes

Primary

MeasureTime frame
Major Adverse Cardiovascular Events;

Secondary

MeasureTime frame
Readmission rate;Quality of life score;

Countries

China

Contacts

Public ContactTang Junnan

The First Affiliated Hospital of Zhengzhou University

qinzhendoctor@163.com+86 15890696166

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026